Precision Neuroscience stock
Private-market facts for current and former Precision Neuroscience employees researching their stock.
Overview
Precision Neuroscience develops a minimally invasive brain-computer interface called the Layer 7 Cortical Interface for treating neurological conditions.
Precision Neuroscience outlook
For employees evaluating Precision Neuroscience equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 4x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Precision Neuroscience shares
Why shareholders consider selling
Shareholders in Precision Neuroscience may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Precision Neuroscience does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Precision Neuroscience stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Precision Neuroscience shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Precision Neuroscience shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Precision Neuroscience shareholders
Exploring equity in Precision Neuroscience often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Precision Neuroscience most recently raised a Series C round in June 2024. Total funding raised to date is approximately $227M.
Founders & company background
Precision Neuroscience was founded in 2021 by Benjamin Rapoport, Michael Mager and is headquartered in New York, NY.
Industry
Similar private companies
Latest Precision Neuroscience news
Frequently asked questions
- Is Precision Neuroscience still a private company?
- Yes, Precision Neuroscience is currently a private company.
- What is Precision Neuroscience's latest funding round?
- Precision Neuroscience's most recent known round is Series C, raised in June 2024.
- What is Precision Neuroscience's valuation?
- Precision Neuroscience's valuation has not been publicly disclosed.
- Who are the investors in Precision Neuroscience?
- Investor information is not currently available.
- Can I sell my Precision Neuroscience stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Precision Neuroscience stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Precision Neuroscience data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.